Celgene, Elan settle Abraxane case for $78M; Health groups ask Novartis to back off Gleevec patent;

Patents on file

@FiercePharma: AZ's dental unit attracts a slew of suitors. Story | Follow @FiercePharma

> Celgene has agreed to pay Elan $78 million to settle a patent infringement lawsuit over the Celgene breast cancer drug Abraxane. In return, Celgene gets a worldwide license to several of Elan's related patents. Report

> Novartis has been urged to drop its "persistent legal actions" in India regarding patent coverage for its anticancer drug Glivec and a challenge to the country's patent laws over fears the latter could hinder access to medicines. News

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

> Irish drugmaker Shire said Watson Pharmaceuticals is seeking marketing approval for a new generic version of the attention deficit hyperactivity disorder treatment Adderall XR. Story

> Valeant Pharmaceuticals posted cash earnings and revenue that topped expectations for its first full quarter since combining with Canada's Biovail, sending its shares higher. Item

> Specialty pharmaceutical company Warner Chilcott's Q4 profit marched past market expectations, helped by sales from products acquired from Novartis and Procter & Gamble. Article

> The FDA has teamed up with Georgetown University to do joint research on public health, ethics, bioinformatics and more, and to cooperate on training and continuing education. Report

Biotech News

@FierceBiotech: Pfizer's crizotinib eliminates signs of advanced lymphoma. Report | Follow @FierceBiotech

@JohnCFierce: Coviden, Valeant vet Chuck Bramlage named CEO at Pearl Therapeutics. News | Follow @JohnCFierce 

> Two European cell therapy companies merge. Item

> FDA hands Protalix a CRL for Gaucher's disease drug. News 

> Osage closes lid on $100M war chest for university start-ups. Story

> Lilly neuroscience chief steps down. Report

And Finally... A rising PSA level isn't such a good predictor of prostate cancer after all and can lead to many unnecessary biopsies, says a large new study. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.